+1 (917) 893 7512

  • #
  • #
  • #

Global Bio CMO Market: Size, Trends & Forecasts (2016-2021)

Publish Date:Jan 2017
No. of Pages:61

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the Report

The report entitled “Global Bio CMO Market: Size, Trends & Forecasts (2016-2021)”, provides analysis of the global bio CMO market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the global biologics market by value, by top selling products, etc.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global bio CMO market has been forecasted for the years 2016-2021, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.

Lonza, Boehringer Ingelheim, Samsung Biologics are key companies in the global bio CMO market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.

Company Coverage

Boehringer Ingelheim
Samsung Electronics (Samsung Biologics)

Executive Summary

Pharmaceutical industry comprise of discovering, developing, producing and marketing of drugs for medical use. World’s largest pharmaceutical firms are located in the North America, Europe and Japan. On the basis of technological platform, pharmaceutical drugs can be divided into small molecule or conventional drugs and large molecule or biologic drugs.

Biologics are made through biological processes and are generally injected. Biologics comprises of vaccines, blood or blood components, somatic cells, gene therapy, etc. Biologics are categorized into first-or second generation, depending on development period and cell line. Biosimilars are the biological that are similar, but not identical to the original product.

CMO or Contract Manufacturing Organization is a third party, which the pharmaceutical firms approach for the manufacturing of components of its product or whole of its product. Bio CMOs are typically used to provide secondary manufacturing coverage for the branded pharmaceutical industry. On the basis of production technology, bio CMOs can be divided into mammalian cell system and microbial system.

The global bio CMO market is expected to increase at a significant growth rate during the forecasted period (2016-2021). The global bio CMO market is supported by various growth drivers, such as increase in pharmaceutical industry, growth in use of biosimilars, potential biologics blockbusters, etc. Yet, the market faces certain challenges, such as risk associated with CMOs, presence of in-house manufacturing facilities of big pharma companies, productivity issues with mammalian cell system, etc.

1. Executive Summary

2. Introduction

2.1 Pharmaceutical Industry Overview
2.1.1 Segments of Pharmaceutical Industry (Drugs)
2.2 Biotechnology/Biologics Overview
2.3 Biosimilar Overview
2.4 Biologics/ Biosimilar Manufacturing
2.5 Bio CMO Overview

3. Global Market Analysis

3.1 Global Biologics Market: An Analysis
3.1.1 Global Biologics Market by Value
3.1.2 Global Biologics Market by Top Selling Drugs
3.1.3 Global Biologics Market by Product in Development
3.1.4 Global Biologics Manufacturing market by Value

3.2 Global Bio CMO Market: An Analysis
3.2.1 Global Bio CMO Market by Penetration Rate
3.2.2 Global Bio CMO Market by Value
3.2.3 Global Bio CMO Market by Capacity
3.2.4 Global Bio CMO Market by Segments

4. Market Dynamics

4.1 Growth Drivers
4.1.1 Global Pharmaceutical Market Growth
4.1.2 Potential Biologics Blockbusters 
4.1.3 Increase in Biosimilar Market
4.1.4 Preference of Biologics Over Small Molecules

4.2 Challenges
4.2.1 Presence for In-House Biopharma Manufacturing
4.2.2 Risk Associated with CMOs
4.2.3 Productivity Issue with Mammalian Cell System

4.3 Market Trends
4.3.1 Big Pharmaceuticals Outsourcing Rate
4.3.2 Capacity Utilization Rate of CMOs
4.3.3 Growth in Mammalian Cell Structure
4.3.4 Stringent Regulatory Requirements for Biologics and Biosimilars

5. Competitive Landscape

5.1 Global Bio CMO Market by Number of Firms
5.2 Global Bio CMO Market Players by Capacity

6. Company Profiling

6.1 Lonza
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Boehringer Ingelheim
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 Samsung Electronics (Samsung Biologics)
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
Figure 1: History of Pharmaceutical Industry
Figure 2: Pharmaceutical Industry Segments
Figure 3: Global Biologics Market by Value; 2016-2021 (US$ Billion)
Figure 4: Global Biologics Market by Products in Development; 2015-2016
Figure 5:Global Biologics Manufacturing Market by Value; 2012-2015 (US$ Billion)
Figure 6: Global Biologics Manufacturing Market by Value; 2016-2020 (US$ Billion)
Figure 7: Global Bio CMO Market by Penetration Rate; 2012-2015
Figure 8: Global Bio CMO Market by Penetration Rate; 2016-2021
Figure 9: Global Bio CMO Market by Value; 2012-2015 (US$ Billion)
Figure 10: Global Bio CMO Market by Value; 2016-2020 (US$ Billion)
Figure 11: Global Bio CMO Market by Capacity; 2014-2020 (KL)
Figure 12: Global Bio CMO Market by Segments; 2015
Figure 13: Global Pharmaceutical Industry by Value; 2012-2020 (US$ Billion)
Figure 14: Global Biosimilar Market; 2015-2020 (US$ Billion)
Figure 15: Global Biopharmaceuticals (Drugs) Market by Segments; 2006-2020
Figure 16: Big Pharmaceuticals Outsourcing Rate; 2015-2020
Figure 17: Capacity Utilization Rate of the Global CMO Industry; 2014-2020
Figure 18: Global Bio CMO Market by Number of Firms; 2015
Figure 19: Global Bio CMO Players by Capacity; 3Q16 (KL)
Figure 20: Lonza Sales; 2011-2015 (US$ Billion)
Figure 21: Lonza Sales by Segments; 2015
Figure 22: Lonza Sales by Region; 2015
Figure 23: Boehringer Ingelheim Sales; 2012-2015 (US$ Billion)
Figure 24: Boehringer Ingelheim Sales by Segments; 2015
Figure 25: Boehringer Ingelheim Sales by Region; 2015
Figure 26: Samsung Electronics Segments Overview
Figure 27: Samsung Electronics Ownership Structure
Figure 28: Samsung Electronics Revenue; 2011-2015
Figure 29: Samsung Electronics Revenue by Segments; 2015
Table 1: Chemical Drugs v/s 1st Generation Biologics v/s 2nd Generation Biologics
Table 2: US Approved Biosimilars
Table 3: Top Selling Biologics Drugs; 2014
Table 4: Potential Biologics; 2016